Form 8-K - Current report:
SEC Accession No. 0001213900-24-068597
Filing Date
2024-08-14
Accepted
2024-08-14 08:11:52
Documents
15
Period of Report
2024-08-14
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0211321-8k_unicycive.htm   iXBRL 8-K 33726
2 PRESS RELEASE OF UNICYCIVE THERAPEUTICS, INC. DATED AUGUST 14, 2024 ea021132101ex99-1_unicycive.htm EX-99.1 54974
3 GRAPHIC ex99-1_001.jpg GRAPHIC 5064
  Complete submission text file 0001213900-24-068597.txt   281219

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE uncy-20240814.xsd EX-101.SCH 3018
5 XBRL LABEL FILE uncy-20240814_lab.xml EX-101.LAB 34240
6 XBRL PRESENTATION FILE uncy-20240814_pre.xml EX-101.PRE 22361
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0211321-8k_unicycive_htm.xml XML 3796
Mailing Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022
Business Address 4300 EL CAMINO REAL, SUITE 210 LOS ALTOS CA 94022 650-384-0642
Unicycive Therapeutics, Inc. (Filer) CIK: 0001766140 (see all company filings)

EIN.: 813638692 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40582 | Film No.: 241204293
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)